Fused Amino Pyrimidine Compounds Treat Tinnitus, Hearing Loss, Meniere's
Summary
USPTO published Patent Application US20260108529A1 on April 23, 2026, filed by inventor Zhong Zhong on October 23, 2025 (Application No. 19366802), covering fused amino pyrimidine compounds for treating tinnitus, acute sensorineural hearing loss, age-related hearing loss, and Meniere's disease. The application discloses therapeutic compositions containing compounds according to Formula (I) or their pharmaceutically acceptable salts, classified under CPC codes A61K 31/5377, A61K 31/519, A61K 31/5517, A61K 45/06, and A61P 27/16.
“Methods of treating tinnitus, acute sensorineural hearing loss, age-related hearing loss, or Meniere's disease, with a compound according to Formula (I), or a pharmaceutically acceptable salt thereof, are provided.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published Patent Application US20260108529A1 disclosing fused amino pyrimidine compounds according to Formula (I) and their use in treating tinnitus, acute sensorineural hearing loss, age-related hearing loss, and Meniere's disease. The application also covers therapeutic compositions containing these compounds or their pharmaceutically acceptable salts. Filing date was October 23, 2025, with Application No. 19366802.
Patent applications are informational publications that establish priority rights and disclose the invention for public notice. They do not create immediate compliance obligations. Third parties reviewing this publication should note the therapeutic claims and CPC classifications (A61K 31/5377, A61K 31/519, A61K 31/5517) to assess potential freedom-to-operate considerations or competitive landscape for similar pharmaceutical compounds.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE
Application US20260108529A1 Kind: A1 Apr 23, 2026
Inventors
Zhong Zhong
Abstract
Methods of treating tinnitus, acute sensorineural hearing loss, age-related hearing loss, or Meniere's disease, with a compound according to Formula (I), or a pharmaceutically acceptable salt thereof, are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of tinnitus, acute sensorineural hearing loss, or Meniere's disease. or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and ring A have any of the meanings herein defined in the description.
CPC Classifications
A61K 31/5377 A61K 31/519 A61K 31/5517 A61K 45/06 A61P 27/16
Filing Date
2025-10-23
Application No.
19366802
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.